News und Analysen
Poxel, winner of the 2023 edition of the I-nov contest
Regulatory News:
POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Linedata and Moovjee Join Forces to Support Tunisian Startups and Entrepreneurs
Linedata, (Euronext Paris: LIN), a global provider of asset management and credit technology, data, and services, announces today its strategic partnership with Moovjee, a regionally recognized
Poxel Announces the Approval of a Prospectus for the Listing of New Shares on Euronext Paris
Regulatory News:
POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Poxel Announces Results from June 21, 2023 Ordinary Annual and Extraordinary General Meeting
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
GEVELOT S.A.: Weekly report of share buyback June 21, 2023
GEVELOT S.A.: Number of Shares and Voting rights 19 June 2023
GEVELOT S.A.: PRESS RELEASE - BOARD OF DIRECTORS JUNE 19, 2023
RALLYE S.A.: Agreement with all Rallye’s creditors benefiting from a trust (fiducie-sûreté) on Casino’s securities
EQS-News: Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023
GEVELOT S.A.: PRESS RELEASE ANNUAL GENERAL MEETING 15 JUNE 2023
Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
RALLYE S.A.: Rallye announces a change in its Executive Management
EQS-News: Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
EQS-News: Abivax appoints Ida Hatoum as Chief People Officer
Carbios strebt nach einer Führungsposition im wachsenden r-PET-Markt mit dem Ziel, durch ein Lizenzierungsmodell einen Anteil von 8 bis 12 % bis 2035 zu erreichen
Carbios (Euronext Growth Paris: ALCRB), ein Biotech-Unternehmen, das in der Entwicklung und Industrialisierung von biologischen Technologien zur Neuerfindung des Lebenszyklus von Kunststoffen und
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a
Carbios Aims to be a Leader in Growing r-PET Market with an Ambition to Capture 8 to 12% Share by 2035 Through Licensing Model
Regulatory News:
Carbios (Euronext Growth Paris: ALCRB), a biotech company pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and
Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that new data will be presented
Voyageurs du Monde: Cyber attack - additional information
Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced two poster presentations at the
Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq
Voyageurs du Monde: Full recovery of activity at Voyageurs du Monde
Voyageurs du Monde: Cyber attack contained at Voyageurs du Monde